专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08778382B2 Tamper resistant transdermal dosage form 有权
公开(公告)号：US08778382B2
公开(公告)日：2014-07-15
申请号：US10835535
申请日：2004-04-30
申请人： Stephen A. Howard , Bruce Reidenberg
发明人： Stephen A. Howard , Bruce Reidenberg
IPC分类号： A61K9/00 , A61F2/00
CPC分类号： A61K9/7061 , A61K9/7092 , A61K31/4468 , A61K31/485
摘要： The invention comprises a transdermal dosage form comprising an active agent component comprising an active agent and an adverse agent component comprising an adverse agent, wherein the active agent component defines at least one channel extending substantially there through.

2. 发明申请

US20080020028A1 TRANSDERMAL DOSAGE FORM COMPRISING AN ACTIVE AGENT AND A SALT AND A FREE-BASE FORM OF AN ADVERSE AGENT 审中-公开
标题翻译：包含活性剂和盐的无菌剂型和不良反应物的自由基形式
公开(公告)号：US20080020028A1
公开(公告)日：2008-01-24
申请号：US11865387
申请日：2007-10-01
申请人： Ihor Shevchuk , Bruce Reidenberg
发明人： Ihor Shevchuk , Bruce Reidenberg
IPC分类号： A61K9/70 , A61K31/4184 , A61K31/439 , A61K31/44 , A61K31/4439 , A61P25/04 , A61K31/445 , A61K31/4535 , A61K31/485 , A61K31/5377
CPC分类号： A61K31/4184 , A61K9/7061 , A61K9/7069 , A61K9/7084 , A61K31/439 , A61K31/44 , A61K31/4439 , A61K31/445 , A61K31/4535 , A61K31/485 , A61K31/5377
摘要： This invention relates to a tamper-resistant transdermal dosage form comprising an active agent, such as an opioid, or a pharmaceutically acceptable salt thereof, a free base of an adverse agent, such as an opioid antagonist, and a pharmaceutically acceptable salt of an adverse agent, such as an opioid antagonist. The transdermal dosage form allows an effective amount of the active agent, or a pharmaceutically acceptable salt thereof, to be transdermally administered to an animal. The invention further relates to methods for treating or preventing pain in an animal comprising contacting the skin of an animal in need thereof with the transdermal dosage form of the invention for an amount of time sufficient to treat or prevent pain.
摘要翻译：本发明涉及一种抗篡改透皮剂型，其包含活性剂，例如阿片样物质或其药学上可接受的盐，不利剂如阿片样物质拮抗剂的游离碱和不利的药学上可接受的盐药物，如阿片拮抗剂。透皮剂型允许有效量的活性剂或其药学上可接受的盐经皮给予动物。本发明还涉及用于治疗或预防动物疼痛的方法，其包括将有需要的动物的皮肤与本发明的透皮剂型接触足以治疗或预防疼痛的时间量。

3. 发明申请

US20060198881A1 Tamper resistant transdermal dosage form 有权
标题翻译：防篡改透皮剂型
公开(公告)号：US20060198881A1
公开(公告)日：2006-09-07
申请号：US11281884
申请日：2005-11-18
申请人： Stephen Howard , Bruce Reidenberg
发明人： Stephen Howard , Bruce Reidenberg
IPC分类号： A61K9/70
CPC分类号： A61K9/7061 , A61K9/7092 , A61K31/4468 , A61K31/485
摘要： The invention comprises a transdermal dosage form comprising an active agent component comprising an active agent and an adverse agent component comprising an adverse agent, wherein the active agent component defines at least one channel extending substantially there through.
摘要翻译：本发明包括透皮剂型，其包含活性剂组分，其包含活性剂和包含不利剂的不利剂组分，其中所述活性剂组分限定至少一个通过其延伸的通道。

4. 发明申请

US20050002997A1 Tamper resistant transdermal dosage form 有权
标题翻译：防篡改透皮剂型
公开(公告)号：US20050002997A1
公开(公告)日：2005-01-06
申请号：US10835535
申请日：2004-04-30
申请人： Stephen Howard , Bruce Reidenberg
发明人： Stephen Howard , Bruce Reidenberg
IPC分类号： A61K9/00 , A61K9/70 , A61K31/4468 , A61K31/485
CPC分类号： A61K9/7061 , A61K9/7092 , A61K31/4468 , A61K31/485
摘要： The invention comprises a transdermal dosage form comprising an active agent component comprising an active agent and an adverse agent component comprising an adverse agent, wherein the active agent component defines at least one channel extending substantially there through.
摘要翻译：本发明包括透皮剂型，其包含活性剂组分，其包含活性剂和包含不利剂的不利剂组分，其中所述活性剂组分限定至少一个通过其延伸的通道。

5. 发明授权

US08790689B2 Tamper resistant transdermal dosage form 有权
标题翻译：防篡改透皮剂型
公开(公告)号：US08790689B2
公开(公告)日：2014-07-29
申请号：US11281884
申请日：2005-11-18
申请人： Stephen A. Howard , Bruce Reidenberg
发明人： Stephen A. Howard , Bruce Reidenberg
IPC分类号： A61F13/02 , A61L15/16 , A61K9/70 , A61F13/00 , A61K31/44
CPC分类号： A61K9/7061 , A61K9/7092 , A61K31/4468 , A61K31/485
摘要： The invention comprises a transdermal dosage form comprising an active agent component comprising an active agent and an adverse agent component comprising an adverse agent, wherein the active agent component defines at least one channel extending substantially there through.
摘要翻译：本发明包括透皮剂型，其包含活性剂组分，其包含活性剂和包含不利剂的不利剂组分，其中所述活性剂组分限定至少一个通过其延伸的通道。

6. 发明申请

US20080233178A1 Abuse Resistant Opioid Transdermal Delivery Device Containing Opioid Antagonist Microspheres 审中-公开
标题翻译：含有鸦片拮抗剂微球的耐药阿片样物质透皮递送装置
公开(公告)号：US20080233178A1
公开(公告)日：2008-09-25
申请号：US10584816
申请日：2005-02-15
申请人： Bruce Reidenberg , Ihor Shevchuk , Lino Tavares , Richard Maskiewicz , Kevin Long , Mohammed Shameem
发明人： Bruce Reidenberg , Ihor Shevchuk , Lino Tavares , Richard Maskiewicz , Kevin Long , Mohammed Shameem
IPC分类号： A61K9/70 , A61K31/485
CPC分类号： A61K31/485 , A61K9/0014 , A61K9/1611 , A61K9/1647 , A61K9/703 , A61K9/7061 , A61K9/7092 , B09B3/0075 , B09B2220/14
摘要： The present invention provides abuse-resistant transdermal delivery devices containing an opioid agonist intended for analgesic purposes in pain patients.
摘要翻译：本发明提供了在疼痛患者中含有用于止痛目的的阿片样物质激动剂的抗滥用透皮递送装置。

7. 发明申请

US20060240085A1 Treatment of dependence withdrawal 有权
标题翻译：治疗依赖戒断
公开(公告)号：US20060240085A1
公开(公告)日：2006-10-26
申请号：US10566121
申请日：2004-07-26
申请人： Bruce Reidenberg , Daniel Spyker
发明人： Bruce Reidenberg , Daniel Spyker
IPC分类号： A61K31/485 , A61K9/70 , A61N1/30
CPC分类号： A61K9/7023 , A61K31/485 , A61L15/00 , B09B2220/14
摘要： Dosage regimens of buprenorphine to treat withdrawal or abstinence syndrome in a drug dependent or opioid tolerant patient who is pregnant are described. The method includes treating withdrawal or abstinence syndrome of the patient by transdermal administration of an amount of buprenorphine effective to reduce withdrawal symptoms. For example, a first buprenorphine-containing transdermal dosage form for a second dosing period that is no more than about 5 days, the second dosage form comprising the same or a greater dosage of buprenorphine than the first dosage form; and a third buprenorphine-containing transdermal dosage form for a third dosing period that is at least 2 days, the third dosage form comprising the same or a greater dosage of buprenorphine than the second dosage form.
摘要翻译：描述了丁丙诺啡在怀孕的药物依赖性或阿片受体患者中治疗戒断或禁欲综合征的剂量方案。该方法包括通过透皮给药一定量的丁丙诺啡来治疗患者的戒断或禁欲综合征，所述丁丙诺啡有效地减少戒断症状。例如，含有不超过约5天的第二给药期的第一种含丁丙诺啡的透皮剂型，所述第二剂型包含与第一剂型相同或更高剂量的丁丙诺啡; 和含有至少2天的第三给药期的第三种含丁丙诺啡的透皮剂型，所述第三剂型包含与第二剂型相同或更高剂量的丁丙诺啡。

8. 发明申请

US20050192308A1 N-but-E-enyl norbuprenorphine and methods of use 审中-公开
标题翻译：非丁烯非诺啡诺及其使用方法
公开(公告)号：US20050192308A1
公开(公告)日：2005-09-01
申请号：US11120524
申请日：2005-05-02
申请人： Donna-Donigi Gale , Bruce Reidenberg , Vinayak Srinivasan
发明人： Donna-Donigi Gale , Bruce Reidenberg , Vinayak Srinivasan
IPC分类号： A61K9/08 , A61K9/10 , A61K9/14 , A61K9/19 , A61K9/20 , A61K9/48 , A61K31/485 , A61P11/14 , A61P25/04 , A61P39/00 , A61P43/00 , C07D489/12
CPC分类号： C07D489/12
摘要： The present invention provides compound having the structure: and pharmaceutically acceptable salts or derivatives thereof, as well as compositions including such compounds. The invention also provides methods of (1) preventing pain, (2) treating pain, (3) inducing sedation, (4) treating opiate addiction, (5) treating opiate withdrawal (abstinence syndrome) and/or (6) treating cough in a patient in need thereof by administering a compound or composition of the invention.
摘要翻译：本发明提供具有以下结构的化合物及其药学上可接受的盐或衍生物，以及包括这些化合物的组合物。本发明还提供了（1）预防疼痛，（2）治疗疼痛，（3）诱导镇静，（4）治疗阿片成瘾，（5）治疗阿片戒断（禁欲综合征）和/或（6）治疗咳嗽通过施用本发明的化合物或组合物来治疗需要的患者。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式